Zobrazeno 1 - 10
of 1 070
pro vyhledávání: '"Lung function decline"'
Autor:
Christian Merlo, Teja Thorat, Lisa J. McGarry, Christina V. Scirica, Maral DerSarkissian, Catherine Nguyen, Yuqian M. Gu, Aruna Muthukumar, Joe Healy, Jaime L. Rubin, M. Alan Brookhart
Publikováno v:
Pulmonary Therapy, Vol 10, Iss 4, Pp 483-494 (2024)
Abstract Introduction Ivacaftor (IVA) has been shown to change the trajectory of cystic fibrosis (CF) disease progression by slowing the rate of lung function decline in clinical studies. Long-term real-world data help to confirm the durability of th
Externí odkaz:
https://doaj.org/article/87a5f56fc12f4e5c98c0384be3eeadd6
Autor:
Grace C. Zhou, Ziyun Wang, Anushka K. Palipana, Eleni-Rosalina Andrinopoulou, Pedro Miranda Afonso, Gary L. McPhail, Christopher M. Siracusa, Emrah Gecili, Rhonda D. Szczesniak
Publikováno v:
Respiratory Research, Vol 25, Iss 1, Pp 1-9 (2024)
Abstract Background Modulator therapies that seek to correct the underlying defect in cystic fibrosis (CF) have revolutionized the clinical landscape. Given the heterogeneous nature of lung disease progression in the post-modulator era, there is a ne
Externí odkaz:
https://doaj.org/article/9daae516b59548be875e50f586862f95
Autor:
Jieun Kang, Kwan Ho Lee, Jae Ha Lee, Yi Yeong Jeong, Sun Mi Choi, Ho Cheol Kim, Joo Hun Park, Hyun-Kyung Lee, Suk Joong Yong, Hye Sook Choi, Hak Ryul Kim, Yangjin Jegal, Won-il Choi, Eun Joo Lee, Jin Woo Song
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
BackgroundPirfenidone is an antifibrotic medication approved for idiopathic pulmonary fibrosis (IPF). Fybro®, a generic version of pirfenidone developed in South Korea, gained approval and is available in 200 mg and in higher-dose formulations of 40
Externí odkaz:
https://doaj.org/article/199f1cae7fb5412fad30620bdfe177c7
Autor:
Christian Rønn, Andreas Dehlbæk Knudsen, Nicoline Stender Arentoft, Rebekka Faber Thudium, Safura-Luise Heidari, Pradeesh Sivapalan, Charlotte S. Ulrik, Thomas Benfield, Sisse Rye Ostrowski, Jens Ulrik Stæhr Jensen, Susanne D. Nielsen
Publikováno v:
Frontiers in Medicine, Vol 11 (2024)
ObjectivesEndothelial injury may promote declining lung function. We aimed to investigate in well-treated persons living with HIV (PLWH) whether elevated levels of thrombomodulin (TM) and syndecan-1 (SDC1) are associated with excess lung function dec
Externí odkaz:
https://doaj.org/article/1cd8f67d512d4673ab66b6ca09dc725e
Autor:
Anna Valeria Samarelli, Roberto Tonelli, Giulia Raineri, Giulia Bruzzi, Dario Andrisani, Filippo Gozzi, Alessandro Marchioni, Matteo Costantini, Luca Fabbiani, Filippo Genovese, Diego Pinetti, Linda Manicardi, Ivana Castaniere, Valentina Masciale, Beatrice Aramini, Luca Tabbì, Simone Rizzato, Stefania Bettelli, Samantha Manfredini, Massimo Dominici, Enrico Clini, Stefania Cerri
Publikováno v:
Frontiers in Oncology, Vol 13 (2024)
IntroductionIdiopathic pulmonary fibrosis (IPF) severely affects the lung leading to aberrant deposition of extracellular matrix and parenchymal stiffness with progressive functional derangement. The limited availability of fresh tissues represents o
Externí odkaz:
https://doaj.org/article/5b37d6660e7f401cb61891a7c2da3885
Autor:
Pablo Mariscal-Aguilar, Luis Gómez-Carrera, Gema Bonilla, Mariana Díaz-Almirón, Francisco Gayá, Carlos Carpio, Ester Zamarrón, María Fernández-Velilla, Isabel Torres, Isabel Esteban, Rita Regojo, Elena Villamañán, Concepción Prados, Rodolfo Álvarez-Sala
Publikováno v:
Frontiers in Public Health, Vol 11 (2024)
IntroductionMajor urban pollutants have a considerable influence on the natural history of lung disease. However, this effect is not well known in idiopathic pulmonary fibrosis (IPF).AimThis study aimed to investigate the effects of air pollution on
Externí odkaz:
https://doaj.org/article/311b575dbe504bf3a70400a31198f5f5
Autor:
Perez-Padilla R, Montes de Oca M, Thirion-Romero I, Wehrmeister FC, Lopez MV, Valdivia G, Jardim JR, Muino A, B Menezes AM
Publikováno v:
International Journal of COPD, Vol Volume 18, Pp 1277-1285 (2023)
Rogelio Perez-Padilla,1 Maria Montes de Oca,2 Ireri Thirion-Romero,1 Fernando C Wehrmeister,3 Maria Victorina Lopez,4 Gonzalo Valdivia,5 Jose R Jardim,6 Adriana Muino,4 Ana Maria B Menezes3 On behalf of the PLATINO Group1National Institute of Respira
Externí odkaz:
https://doaj.org/article/5420bc2856304d1cbe2f22c6c1a34701
Autor:
Marianna Štefániková, Martina Doubková, Petra Ovesná, Martina Šterclová, Ladislav Lacina, Monika Žurková, Martina Plačková, Vladimír Bartoš, Ivana Janíčková, Radka Bittenglová, Jan Anton, Ľubica Sýkorová, Vladimíra Lošťáková, Pavlína Musilová, Hana Šuldová, Radka Mokošová, Jurij Didyk, Lenka Šišáková, Pavlína Lisá, Jaroslav Lněnička, Hana Dařičková, Daniel Doležel, Jana Pšikalová, Richard Tyl, Renata Králová, Martina Koziar Vašáková
Publikováno v:
BMC Pulmonary Medicine, Vol 23, Iss 1, Pp 1-9 (2023)
Abstract Introduction The antifibrotic drug nintedanib is used for the treatment of idiopathic pulmonary fibrosis (IPF). We analysed the effect of nintedanib on antifibrotic treatment outcome in real-world cohorts of Czech EMPIRE registry. Patients/m
Externí odkaz:
https://doaj.org/article/354e93acae574d0789b4d40b679b4189
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.